Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients

[1]  G. Argenziano,et al.  Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients , 2020, British Journal of Cancer.

[2]  Christoph H. Emmerich,et al.  Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages , 2019, The EMBO journal.

[3]  P. Ohashi,et al.  Turning the Tide Against Regulatory T Cells , 2019, Front. Oncol..

[4]  Reinhard Dummer,et al.  High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.

[5]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[6]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[7]  S. Dawson,et al.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.

[8]  S. Staibano,et al.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma , 2017, Oncotarget.

[9]  R. Fietkau,et al.  Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression—A Case Report from the IMMO-GLIO-01 Trial , 2017, Front. Neurol..

[10]  P. Ascierto,et al.  FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy , 2017, Cancer Immunology, Immunotherapy.

[11]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[12]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[13]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[14]  L. Zitvogel,et al.  Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Ascierto,et al.  Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients , 2015, Pigment cell & melanoma research.

[16]  M. Masullo,et al.  FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma , 2015, Nucleic acids research.

[17]  D. Rimm,et al.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites , 2015, Clinical Cancer Research.

[18]  S. Ostrand-Rosenberg,et al.  The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity , 2014, The Journal of Immunology.

[19]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[20]  Peter Vogel,et al.  mTORC1 couples immune signals and metabolic programming to establish Treg cell function , 2013, Nature.

[21]  S. Romano,et al.  The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer , 2011, Current medicinal chemistry.

[22]  P. Tassone,et al.  Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy , 2010, Journal of immunotherapy.

[23]  J. Skolnick,et al.  Structure‐based classification of 45 FK506‐binding proteins , 2008, Proteins.

[24]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[25]  S. Venuta,et al.  Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. , 2004, European journal of cancer.

[26]  A. Kumar,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Regulate Myeloperoxidase Expression in Macrophages by an Estrogen-dependent Mechanism Involving the -463GA Promoter Polymorphism* , 2004, Journal of Biological Chemistry.

[27]  Giulio Superti-Furga,et al.  A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.

[28]  M. Martin,et al.  Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. , 1997, Biochemical and biophysical research communications.

[29]  M. Martin,et al.  FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition , 1995, Molecular and cellular biology.

[30]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[31]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[32]  S. Staibano,et al.  Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells , 2010, Cell Death and Differentiation.

[33]  G Fischer,et al.  Regulation of peptide bond cis/trans isomerization by enzyme catalysis and its implication in physiological processes. , 2003, Reviews of physiology, biochemistry and pharmacology.